Today: 20 May 2026
Oklo stock slips 3% at the close as insiders reshuffle holdings; what traders watch next
31 December 2025
2 mins read

Oklo stock slips 3% at the close as insiders reshuffle holdings; what traders watch next

NEW YORK, December 30, 2025, 21:24 ET — Market closed.

  • Oklo closed down 3.3% at $71.62 on Tuesday, after trading between $71.38 and $74.73.
  • A new SEC Form 4 filing disclosed large share transfers into family trusts by an Oklo insider, with no shares sold for cash.
  • U.S. stocks ended slightly lower in holiday-thin trading, a backdrop that can amplify moves in volatile, smaller-cap names.

Oklo Inc. shares fell 3.3% on Tuesday to end at $71.62, lagging the broader market in the year’s final trading week.

The slide matters now because liquidity is thin into year-end, and price swings can get sharper in high-volatility stocks when fewer investors are active.

Oklo, which says it is a fission technology and nuclear fuel recycling company, has traded as a high-beta nuclear-power bet, leaving it sensitive to shifts in risk appetite and any signal on funding or regulatory timelines.

On Wall Street, the S&P 500 and Nasdaq closed fractionally lower in choppy trading on Tuesday, Reuters reported, as investors rotated out of parts of technology and rebalanced portfolios. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters

Other nuclear and uranium-linked names were also lower on the day, though by less than Oklo, with NuScale Power, Centrus Energy and Cameco all ending down.

A Form 4 filed with the U.S. Securities and Exchange Commission on Monday showed Caroline Cochran, identified as a director and Oklo co-founder and COO, transferred 7.58 million Class A shares for no consideration to a family trust, among other trust-related moves. The filing also described an additional 7.85 million-share transfer by the reporting person’s spouse to a separate family trust, also for no consideration.

Form 4s are required disclosures of insider transactions. The filing described gifts and transfers to trusts, including grantor retained annuity trusts — vehicles commonly used for estate planning — rather than open-market sales.

Investors also have an eye on Washington policy headlines tied to advanced nuclear fuel and reactor development. In October, Reuters reported the U.S. Department of Energy expected to begin announcing by Dec. 31 which companies would take surplus plutonium for eventual processing into nuclear reactor fuel.

Macro policy remains part of the tape for speculative growth names: Reuters reported Tuesday that Fed officials debated sharply before agreeing to a quarter-point rate cut at their December meeting, with the minutes highlighting divisions over how quickly to ease.

Before the next session, U.S. stock markets are set to operate regular hours on Wednesday, Dec. 31, and remain closed on Thursday, Jan. 1, MarketWatch reported. The U.S. bond market is slated to close early at 2 p.m. ET on Dec. 31.

Traders will also watch Wednesday’s U.S. initial jobless claims report at 8:30 a.m. ET and the S&P CoreLogic Case-Shiller home price index at 9 a.m. ET, MarketWatch reported — data that can move rate expectations in thin conditions.

On the chart, Tuesday’s $71.38 low is the nearest reference point for bulls, while $74.73 marks the session high that would need to be reclaimed to signal stabilization. Oklo’s 52-week range sits at $17.42 to $193.84, underscoring how quickly the stock can reprice.

The next major scheduled corporate catalyst on many calendars is the company’s next earnings update; MarketWatch lists March 30, 2026 as the next earnings date. Until then, investors are likely to focus on fresh filings, any regulatory or government-program updates, and whether volume returns after the holidays.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Circle (CRCL) stock slips into year-end close as Fed minutes keep rate bets in focus
Previous Story

Circle (CRCL) stock slips into year-end close as Fed minutes keep rate bets in focus

Al-Arafah Islami Bank, Provati Insurance sign deal to digitise premium payments in Bangladesh
Next Story

Al-Arafah Islami Bank, Provati Insurance sign deal to digitise premium payments in Bangladesh

Go toTop